ABL Diagnostics

Equities

ABLD

FR001400AHX6

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 05:30:11 2024-04-30 am EDT			5-day change	1st Jan Change
3.06 ^EUR	0.00%		-3.77%	-68.45%

2023	ABL Diagnostics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	ABL Diagnostics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Fauvet-Girel Reports Earnings Results for the Full Year Ended December 31, 2020

April 23, 2021 at 08:36 am EDT

Fauvet-Girel announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was EUR 1. Operating loss was EUR 91,161 compared to EUR 69,263 a year ago. Net loss was EUR 89,296 compared to EUR 62,937 a year ago.

Latest news about ABL Diagnostics

ABL Diagnostics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 21	CI
ABL Diagnostics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-07-31	CI
Roche, ABL Diagnostics Sign Distribution Partnership in South Africa	23-03-27	MT
ABL Diagnostics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-01	CI
Advanced Biological Laboratories S.A. completed the acquisition of a 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons.	22-08-30	CI
ABL Diagnostics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-20	CI
Advanced Biological Laboratories S.A. agreed to acquire the remaining 3.3% stake in Fauvet-Girel for €0.13 million.	21-10-14	CI
Advanced Biological Laboratories S.A. acquired 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons for €3.9 million.	21-10-14	CI
Advanced Biological Laboratories S.A. acquired 96.7% stake in Fauvet-Girel from STE Parisienne De Construction Et De Location and seven natural persons for €3.9 million.	21-10-14	CI
Fauvet-Girel Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-23	CI
Bernard Krief Consultants SA completed the acquisition of 96.7% stake in Fauvet-Girel from Spaclo SA and members of the founding family.	19-12-09	CI
Bernard Krief Consultants SA signed an agreement to acquire 96.7% stake in Fauvet-Girel from Spaclo SA and members of the founding family for €8.1 million.	18-06-19	CI
Fauvet-Girel(ENXTPA:FAUV) dropped from CAC All-Tradable Index	12-06-17	CI
Fauvet-Girel(ENXTPA:FAUV) dropped from CAC Small Index	12-06-17	CI

Chart ABL Diagnostics

Duration

Period

More charts

Company Profile

ABL Diagnostics specializes in the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases (AIDS, viral hepatitis and tuberculosis) by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. Export accounts for 69.3% of net sales.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABL DIAGNOSTICS	-68.45%	52.83M
ABBOTT LABORATORIES	-2.54%	186B
MEDTRONIC PLC	-1.85%	107B
BECTON, DICKINSON AND COMPANY	-4.26%	67.44B
DEXCOM, INC.	+1.39%	50.03B
CENCORA, INC.	+16.82%	47.81B
HOYA CORPORATION	+4.79%	41.03B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.85B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	25.82B
TERUMO CORPORATION	+16.55%	24.74B

Other Medical Equipment, Supplies & Distribution